This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Safe and Effective Prescribing of Opioid Analgesics: A Hands-on, Case-based Clinical Curriculum in Primary Care

Safe and Effective Prescribing of Opioid Analgesics: A Hands-on, Case-based Clinical Curriculum in Primary Care

Format

Case-Based Decision Tree

Time to Complete

3 hours

Released

December 2, 2019

Expires

December 2, 2020
Add to Queue


Maximum Credits

3.00 / AMA PRA Category 1 CreditsTM
3.00 / CNE Contact Hours
3.00 / CE for Pharmacists (0.30 CEUs)

Accredited Provider

Through a series of cases, this activity has been designed to sufficiently address the FDA’s new “Opioid Analgesics Blueprint for Prescriber Education.”

Provided by MediCom Worldwide, Inc.

Commercial Supporter

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration.

Program Description

This activity will explore appropriate use of opioid therapies in pain, where opioids fit in a comprehensive treatment plan that included non-pharmacologic and non-opioid strategies, and the role of a clinician in the safe prescribing of opioid medications to patients in acute or chronic pain. This activity will not cover palliative care or end-of-life care patients in depth. In addition, this activity will address the risks and benefits of this class of medications and the tools needed to properly evaluate a patient’s pain and risk of misuse. To ensure the best possible outcomes for patients, this program will cover the entire FDA Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. Each Blueprint element will tie into a real-life patient case that the learner will explore and assist in the safe and effective treatment, from initial visit to managing follow-up.

Agenda

IR Opioids for Acute Pain Management – Jeffrey A. Gudin, MD, and Charles P. Vega, Jr., MD, FAAFP
ER/LA Opioids for Chronic Pain Management – Jeffrey A. Gudin, MD, and Charles P. Vega, Jr., MD, FAAFP
Opioids, Pain Management and Addiction – Martin D. Cheatle, PhD, and Charles P. Vega, Jr., MD, FAAFP

Intended Audience

This activity is designed for physicians, physician assistants, nurses, pharmacists, dentists, and allied health professionals whose practices manage acute and chronic pain.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Apply principles of pain pathophysiology and management in the development of individualized treatment strategies for patients with acute and chronic pain
  • Effectively assess patients who are candidates for treatment with IR or ER/LA opioids
  • Compare and contrast analgesic options for acute and chronic pain, including non-pharmacologic strategies, non-opioids, and IR and ER/LA opioids
  • Demonstrate how to initiate therapy, modify dose, and discontinue use of IR and ER/LA opioid analgesics within a strategic treatment plan
  • Integrate knowledge of IR, ER, LA, and abuse-deterrent formulation (ADF) opioids into individualized short- and long-term treatment plans that maximize safety and efficacy
  • Counsel patients and caregivers regarding the safe use of both IR and ER/LA opioid analgesics, including storage and disposal
  • Identify principles of addiction medicine and an understanding of opioid use disorder in managing patients who may be prescribed IR or ER/LA opioids

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty

Martin D. Cheatle, PhD (Content Development)
Associate Professor of Psychology in Psychiatry
Department of Psychiatry
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Cheatle has received honoraria as a consultant from Rockpointe Corporation.

Jeffrey A. Gudin, MD (Course Director)
Director, Pain Management and Wellness Center
New York
Clinical Associate Professor of Anesthesiology
Rutgers New Jersey Medical School
Newark, New Jersey

Dr. Gudin has received honoraria related to speakers’ bureau activities from AstraZeneca, Daiichi Sankyo Company Limited, Salix Pharmaceuticals, and SCILEX Pharmaceuticals, Inc., and formal advisory activities from AcelRx Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., and Recro Pharma, Inc., as well as consultant fees from Averitas Pharma, Inc., Mallinckrodt Pharmaceuticals, Nektar, PERNIX Therapeutics, Quest Diagnostics, and SCILEX.

Charles P. Vega, Jr., MD, FAAFP (Content Development)
Health Sciences Clinical Professor
University of California, Irvine
Irvine, California

Dr. Vega has disclosed no relevant financial relationships.

David S. Craig, PharmD (Content Advisor)
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Pharmacist Lead
Pain Management and Palliative Care Services
Moffitt Cancer Center and Research Institute
Tampa, Florida

Dr. Craig has received consultant fees from Nektar Therapeutics and SpecGx LLC.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke and Andrea Mathis, Project Managers, Andrew Bowser, Medical Writer, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Andrew Bowser has disclosed that his spouse/life partner has received honoraria related to speaker’s bureau activities from Takeda Pharmaceutical Company Limited and as a consultant from ALK-Abelló A/S, CSL Behring, Pharming Group NV, and Shire.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Credit

3.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

MediCom Worldwide, Inc. designates this enduring material for a maximum of 3.00 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

3.00

Type

CNE Contact Hour(s)

Accreditation Statement

MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380.

Designation Statement

MediCom designates this CNE activity for 3.0 contact hours. Program Number: 19-006-096

Credit

3.00

Type

CE for Pharmacists

Accreditation Statement

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 3.0 contact hours of Continuing Education Credit. 827-0000-19-006-H01-P. Application-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Instructions for Participation and Credit

This activity is eligible for credit through December 2, 2020. After this date, this activity will expire and no further credit will be awarded.

1. Review the target audience, learning objectives, and faculty disclosures.
2. Complete a pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Privacy Policy

Copyright

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue